Trial Profile

A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the Treatment of Metastatic Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Octreotide (Primary) ; Octreotide (Primary) ; Capecitabine; Lapatinib
Indications Diarrhoea
Focus Therapeutic Use
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK; Novartis Pharmaceuticals

18 Dec 2021 This trial has been completed in Italy (global end date: 19 Oct 2019), according to European Clinical Trials Database record.
02 May 2019 This trial has been completed in France. (global end date: 19 Oct 2019)
28 Mar 2019 This trial has been completed in UK - MHRA according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com